Biotech News

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio (PASG)Passage Bio2026-04-20 11:00 ESTClinical readout

PASG (PASG) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is pasg.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

NTLAIntellia2026-11-04 13:00 EST

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

ANVSAnnovis Bio2026-10-30 21:00 EST

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

ACIUAC Immune2026-09-23 11:00 EST

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

View all latest news

Passage Bio

Passage Bio is a gene-therapy company focused on rare and neurological diseases. Its business has centered on the challenge of translating genetic medicine into the central nervous system.

Recent company news

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

PASGPassage Bio2026-04-20 11:00 EST

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PASGPassage Bio2026-03-03 12:00 EST

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

PASGPassage Bio2026-02-19 12:00 EST

Passage Bio to Participate in Upcoming Investor Conferences

PASGPassage Bio2025-11-10 21:15 EST

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Stock data

Close: 3.46 USD
Market cap: 18.91M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States